ArticleJournal of endocrinological investigation2026
Comparison of pre-operative calcitonin, FNAC, and ultrasound risk stratification systems in patients with medullary thyroid carcinoma.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How to manage medullary thyroid carcinoma: current treatment strategies.Drugs in context · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
contextAlthough the diagnostic performance of calcitonin (CTN) in revealing medullary thyroid carcinoma (MTC) has been widely demonstrated, to date, neck ultrasound (neck US) and FNAC remain the first-line tools in searching for malignancy in thyroid nodules.
objectiveThis study aims to determine which tool is more effective at suggesting MTC among preoperative CTN values and FNAC, compared with the estimated risk of malignancy at neck US according to the 5 main risk stratification systems (RSS), in a population of patients with already diagnosed MTC.
methodsWe evaluated preoperative serum CTN, FNAC, and neck US data in 104 patients with sporadic MTC (2014-2020) managed at the Unit of Endocrinology of the Pisa University Hospital, Italy.
resultsAccording to the neck US RSS, 59.6% of patients were classified as the intermediate-low suspicion (ILS) and 40.4% as the high suspicion (HS) group. FNAC, performed according to clinical judgment in 85/104 (81.7%) cases, was diagnostic of MTC in only 45.9% of cases. Moreover, according to the guidelines, 39 (62.9%) nodules in the ILS and 14 (33.3%) in the HS group would not even be submitted for FNAC. Of note, most of these MTCs had tumor dimensions > 1 cm and/or lymph node metastases. Conversely, the preoperative CTN values suggested at least a suspicion of MTC in both US risk groups and across all MTC US dimension categories, including microcarcinomas.
conclusionsAmong patients with a confirmed diagnosis of MTC, serum CTN values were the most reliable parameter, outperforming ultrasound features and FNAC in diagnostic accuracy. Delaying or failing to diagnose MTC is undesirable if the aim is to achieve early diagnosis and effective treatment of these patients.
Indexed as
Identifiers
41774330What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.